Frontlight ResearchEarly access
TerminatedPhase 1
A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
Key facts
- Who runs it
- IGM Biosciences, Inc.
- Where
- Palo Alto, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 2 people enrolled
- Started
- 29 May 2024
- Ended
- 21 Jan 2025
- Type of study
- Interventional
- Treatments tested
- Imvotamab
- Record updated
- 11 February 2025
- Why it stopped
- Program Discontinuation
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age ≥ 18 years at the time of signing ICF
- Diagnosis of probable or definite IIM according to the 2017 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for IIM with subgroup classification of either DM, polymyositis (PM), anti-synthetase syndrome, or immune-mediated necrotizing myositis (IMNM)
- Active IIM despite treatment with corticosteroids and at least 1 immunosuppressive or immunomodulatory standard-of-care agent determined at the discretion of the investigator after at least 3 months of treatment
- If using oral corticosteroids (OCS), must be on a stable dose equivalent to ≤ 30 mg/day of prednisone for at least 4 weeks prior to first study treatment
Who cannot take part
- Receipt of an investigational therapy less than 12 weeks or 5 drug-elimination half-lives (whichever is longer) prior to first administration of study treatment and during the study
- Has inclusion body myositis or myositis-associated with other connective tissue disease
- Pregnant or breastfeeding or intending to become pregnant during the study or within 3 months after the final dose of imvotamab
Where in United States
- Standford UniversityPalo Alto, United States
About the trial
What the trial wants to find out
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with Moderate-Severe Idiopathic Inflammatory Myopathies who have failed prior therapies.
Read full original descriptionShow less
Participants will be given imvotamab through a vein (i.e., intravenously).
The group in the trial
- Imvotamab (Dose Escalation)Treatment being tested
Imvotamab administered intravenously
Treatment: Imvotamab
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Adult Participants With Active, Refractory Moderate-Severe Idiopathic Inflammatory Myopathies
- Record updated
- 11 February 2025